Showing results (2221-2230 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|March 5, 2020
Modeling Heterogeneity in Patients' Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class ApproachesMarco Boeri, Daniel Saure, Alexander Schacht, et al.
Pharmacoeconomics|July 7, 2021
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 ObservationsJenny M Norlin, Klas Kellerborg, Per Odin
Pharmacoeconomics|May 21, 2014
The economic burden of head and neck cancer: a systematic literature reviewErika Wissinger, Ingolf Griebsch, Juliane Lungershausen, et al.
Pharmacoeconomics|June 5, 2014
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in SpainAntonio Gómez-Outes, Cristina Avendaño-Solá, Ana Isabel Terleira-Fernández, et al.
Pharmacoeconomics|March 17, 2015
Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in ThailandNaruemon Bamrungsawad, Nathorn Chaiyakunapruk, Nilawan Upakdee, et al.
Pharmacoeconomics|May 6, 2023
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job CharacteristicsBeata Koń, Michał Jakubczyk
Pharmacoeconomics|November 15, 2012
Chemotherapy administration: modelling the costs of alternative protocolsPhilip Haywood, Johan de Raad, Kees van Gool, et al.
Pharmacoeconomics|May 27, 2014
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New ZealandRachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, et al.
Pharmacoeconomics|March 31, 2021
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, CanadaYong-Jin Kim, Mark Oremus, Helen H Chen, et al.
Pharmacoeconomics|March 30, 2021
Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic ReviewAlfredo Palacios, Carlos Rojas-Roque, Lucas González, et al.
Pageof 336